Long-acting sstr2 antagonists and Pretargeted Alpha Therapy: a super combination for safer and more efficient treatment of neuroendocrine tumors
![](https://www.erasmusmc-rdo.nl/wp-content/plugins/js_composer/assets/vc/no_image.png)
Project summary
Radionuclides are promising molecules in cancer treatment. However, due to side effects on healthy tissue, it is not always possible to administer a sufficiently high dose. The aim of this research is to enable a more effective treatment of neuroendocrine tumors with radionuclides.
Impact
If this research is successful, the step towards a patient study can be made. The researchers expect to be able to tackle some practical problems surrounding PRRT with this new method. The new method can help ensure that a higher dose of radioactive molecules reaches the tumor more efficiently and thus kills the cells with fewer side effects. That could make healing possible, or at least survive longer with a better quality of life.
More detailed information
Principal Investigator:
dr. Yann Seimbille
Role Erasmus MC:
Coördinator
Department:
Radiologie & Nucleaire Geneeskunde
Project website:
Funding Agency:
KWF
![KWF-logo-vierkant-800x800-jmm](https://www.erasmusmc-rdo.nl/wp-content/uploads/2022/06/KWF-logo-vierkant-800x800-jmm.png)